CipherBio PRO Cardiovascular Disease Insight explores the most targeted condition area for medical devices. The insight includes information on innovative cardiovascular medical device companies that received funding from 2019-2021. Since 2019, 379 VCs have invested $11.4B in 163 companies in life science cardiovascular disease medical devices. 63 of these devices are already on the market.












Top Exits 2019-2021

Company Round Amount
Biotelemetry, Inc. Acquisition $2.8B
Baylis Medical Company Acquisition $1.8B
Cardiva Medical Acquisition $510M
HeartFlow IPO $400M
Bardy Diagnostics Acquisition $375M


Top Private Rounds 2019-2021

Company Round Amount
Valgen Medtech Series B $188M
WEGO Intervention Series A $155M
Element Science Series C $146M
Kardium Series B $115M
Peijia Medical Series C $100M


Top Accelerator: MedTech Innovator

56 companies in cardiovascular disease have raised close to a billion dollars thanks to MedTech Innovator. MedTech Innovator is the top accelerator in the cardiovascular medical device space, and 23 of their portfolio companies have ready for market products.

MedTech Innovator Investments

Landscape analysis is critically important to key stakeholders in the medtech industry, and I was blown away by CipherBio’s new Cardiovascular Disease Insights. Strategics and venture funds are always looking to get the full picture of the cardiovascular product pipeline as are the many innovators in the space. The CipherBio Insights provides a single source to view everything in the pipeline along with indications, approaches, development stages, and it even offers the ability to download. I highly recommend CipherBio PRO to the emerging companies in MedTech Innovator’s portfolio as well as investors and large cap medtech companies. I’ve never seen anything like this.

It was thrilling to see MedTech Innovator’s cardiovascular portfolio top the CipherBio list. If you don’t see your name on this list, you have time to apply for 2022 by Feb 15th. Apply @

Paul Grand, CEO @ MedTech Innovator


Top Indications in Cardiovascular Disease

The cardiovascular indication with the most companies and funding is heart failure. 35 companies have raised a combined total of $1.5 billion. Minneapolis-based CVRx Inc., which is developing Barostim™ Baroreflex Activation Therapy (BAT) for heart failure treatment has had the biggest raise. CVRX IPO’d for $144.9M in early July 2021.


Indication Amount
 Heart Failure $1.5B
 Cardiac Arrhythmias $914M
 Heart Disease $419M
 Atrial Fibrillation (AF) $365M
 Stroke $516M


Most Active Investors in 2021

The VCs that invested in the most companies were Sofinnova Partners, Deerfield Management, 415 CAPITAL, Broadview Ventures, and Ascension Ventures, who invested in a total of 23 companies and participated in rounds totaling $923 Million.

Investors by Deal Count


Top Acquisitions in 2021

2021 saw a huge increase in funding compared to previous years. Topping the deal size list are three acquisitions: Royal Philips’s $2.8 Billion acquisition of BioTelemtry, Boston Scientific’s $1.8 Billion acquisition of Baylis Medical Company, and Haemonetics $510 Million acquisition of Cardiva Medical.


Company Acquirer Deal Date Amount
Biotelemetry, Inc. Royal Philips Feb  2021 $2.8B
Baylis Medical Company Boston Scientific Jun 2021 $1.8B
Cardiva Medical Haemonetics Oct 2021 $510M
Bardy Diagnostics Hillrom Aug 2021 $375M
Ascyrus Medical CryoLife Sep 2021 $200M
Cheetah Medical Baxter International Sep 2021 $190M


With the rising prevalence of debilitating cardiovascular diseases, the demand for treatments has also risen. Fortunately, the medical device field is rapidly growing to develop life-saving, innovative treatments to combat these conditions. 100 companies in the insights remain in clinical trials, and with growing access to the FDA approval process, these smaller, private companies are able to more easily put their devices through trials with the potential to reach the market.

See Cardiovascular Disease Insights

Request CipherBio PRO Demo

You May Also Like

Most Active Corporate VCs in the Life Science Industry

Co-authored by Matt Gibbs CipherBio@svb and Steve Agular SVB Managing Director, VC…
MicroBiome Insights

64 Microbiome Biotechs Raise $1.6 Billion in Investments

In the last decade, a relatively uncharted field exploded in the life…
CipherBio 2020 Biotech Industry Report

2020 Biotech Funding Overview

It has been an unprecedented year so far for Biotech industry and…
Q2 2020 Life Science Accelerators Insights

Q2 2020 Life Science Accelerators Insights

Co-authored by Matt Gibbs @cipherbio_gibbs, Ben Johnson SVB National Head of Early…